the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
Status:
Unknown status
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
A total of 210 coronary atherosclerosis patients without indications for stent implantation
are included. The baseline values of platelet aggregation rate, plasmaThromboxaneB2 and
urinary 11-dh ThromboxaneB2 are measured by Light Transmittance Aggregometry method and ELISA
after aspirin 100 mg /d ≥5d. Then the patients are randomly divided into 7 groups: Group1:
aspirin 100 mg/d; Group2: aspirin 100 mg /2d; Groups3: aspirin 100 mg / 3d; Groups4: morning
50mg evening 50mg; Group5: aspirin 75mg / d; Group6: aspirin 50mg / d; Group7: indobufen100mg
bid. One month later,arachidonic acid-induced platelet aggregation rate , plasma TXB2 and
urine 11-dh TXB2 are analyzed again. All patients are followed-up for 1 year. The stomach
Intestinal reactions, small bleeding events are recorded.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University